Discontinued — last reported Q4 '24
Emgality® — Revenue
Eli Lilly Emgality® — Revenue increased by 23.1% to $249.80M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 34.2%, from $186.10M to $249.80M. Over 3 years (FY 2021 to FY 2024), Emgality® — Revenue shows an upward trend with a 14.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market share or higher patient adoption for the migraine therapy, while a decrease may signal increased competition from biosimilars or alternative treatments.
Detailed definition
This metric represents the total gross sales generated from the specific pharmaceutical product line dedicated to migrai...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or therapeutic franchises at other large-cap pharmaceutical companies, often evaluated against total segment revenue growth rates.
lly_segment_emgality_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $156.30M | $140.00M | $161.40M | $149.30M | $157.50M | $168.50M | $175.60M | $154.30M | $169.30M | $168.50M | $186.10M | $225.70M | $192.00M | $202.90M | $249.80M |
| QoQ Change | — | -10.4% | +15.3% | -7.5% | +5.5% | +7.0% | +4.2% | -12.1% | +9.7% | -0.5% | +10.4% | +21.3% | -14.9% | +5.7% | +23.1% |
| YoY Change | — | — | — | — | +0.8% | +20.4% | +8.8% | +3.3% | +7.5% | +0.0% | +6.0% | +46.3% | +13.4% | +20.4% | +34.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's emgality® — revenue?
- Eli Lilly (LLY) reported emgality® — revenue of $249.80M in Q4 2024.
- How has Eli Lilly's emgality® — revenue changed year-over-year?
- Eli Lilly's emgality® — revenue increased by 34.2% year-over-year, from $186.10M to $249.80M.
- What is the long-term trend for Eli Lilly's emgality® — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's emgality® — revenue has grown at a 14.7% compound annual growth rate (CAGR), from $577.20M to $870.40M.
- What does emgality® — revenue mean?
- The total annual revenue generated from sales of the company's migraine medication product line.